Hair Transplantation

  • Author: Jeffrey S Epstein, MD, FACS; Chief Editor: Arlen D Meyers, MD, MBA  more...
Updated: Aug 13, 2015


Hair loss occurs in more than 60% of men and in approximately 10% of women. Although a lack of scalp hair can potentially increase the risk of actinic damage and skin cancer, male and female pattern baldness are conditions that are, with few exceptions, treated electively.

Balding is a major concern for many, and surgery to treat hair loss (ie, hair transplantation) is the most common cosmetic surgery procedure performed on men today. Yet, the market for hair transplantation is dwarfed by the immense market for products that treat hair loss without surgery. These products, which include shampoos, hair-care cosmetics, scalp massagers, laser combs, and many more, have no proven efficacy except for their ability to temporarily increase the volume of existing hair, resulting in a denser appearance than before. Exceptions are the two medications the US Food and Drug Administration (FDA) approved: minoxidil (Rogaine, available over the counter in the United States) and finasteride (Propecia, available by prescription only for men), which have limited but definite benefit.

Interest in hair transplantation will probably increase as knowledge that most modern hair-transplantation techniques can create virtually undetectable restoration spreads, as shown below. To this day, hair transplantation remains the treatment of choice for most patients with hair loss.

Case 1. Views before and 6 months after a procedur Case 1. Views before and 6 months after a procedure performed by using 2000 follicular-unit micrografts.

One of the most rapidly growing segments of hair transplantation is hair transplantation in women. Surgical hair restoration was developed for and has traditionally been used in males. Newer techniques are more adaptable to females.

Hair transplantation is used to treat various forms and degrees of permanent alopecia in both men and women. Intact hair follicles may be harvested from within the safe donor area (SDA) of a patient's scalp by either follicular unit strip surgery (FUSS) or follicular unit extraction (FUE); each harvesting method has unique advantages and disadvantages. The refinement of follicular unit transplanting over the last decade has led to markedly improved hair survival and natural-appearing results (see the image below).[1, 2, 3]

Case 2. Views before and after 3500 follicular-uni Case 2. Views before and after 3500 follicular-unit micrografts performed in 2 procedures.


Some say, "A bad hair day is better than a no hair day." For millions of individuals, hair loss is a major problem associated with loss of self-esteem, insecurity, and even depression. Hair loss can range from early thinning or hairline recession to complete loss of hair along the top and upper sides of the head.

A full head of hair contains approximately 100,000 hairs. (People with red or blonde hair have somewhat more than this.) The loss of up to 30% of the number that was present during the peak of adolescence that occurs by middle age is part of the normal aging process. For thinning to become cosmetically noticeable, at least 50% of the hairs must have fallen out in a particular area. Loss of a smaller percentage than this generally does not result in the cosmetic appearance of hair loss. In addition to the loss of the number of hairs, the hair loss process causes individual hairs to thin, which further contributes to the appearance of hair loss.

The Norwood Classification System recognizes and categorizes the typical sequence of the hair loss process in men.[4] Early in the process (types 1-3), the hairline recedes, typically led by frontotemporal recessions. In the latter stages (types 4-7), progression of hair loss at the vertex (crown) gradually meets and joins the progressive hairline recession, resulting in varying sizes (in both coronal and sagittal dimensions) of the confluent vertex with frontotemporal regions of baldness.

For women, the development of androgenic alopecia is classified into three stages. The typical pattern of hair loss in women is progressive diffuse thinning in an oval area along the top of the scalp. Hair loss along the hairline is usually spared.

During the 1990s, leaders in hair transplantation debated several topics. Out of the debates emerged several commonly (though not unanimously) accepted truths.

First is the superiority of hair grafting versus bald-scalp reduction and scalp-flap surgery in almost all situations. Second is the inferiority of lasers to conventional cutting devices to form the recipient site. Third is the acceptance of large-session micrografting, also termed the megasession, in which 2000 or more grafts can be transplanted safely in a single procedure.

Nearly all hair-transplant specialists agree on the superiority of follicular-unit micrografting over traditional micrografting and minigrafting. Although follicular-unit micrografting is technically more demanding and time-consuming than other procedures, it yields superior results in terms of creating a natural appearance because hairs are transplanted as they grow naturally in the scalp. The procedure also enables dense graft placement when desired because individual grafts are small and thereby permitted small recipient sites and closer spacing. In addition, follicular-unit grafting reduces accidental transection of hair follicles during the graft-dissection process because dissection is performed under microscope visualization; therefore, wastage of valuable donor hairs can be reduced.

The future of hair restoration is exciting, primarily because of medical advances. Improved effectiveness of control of hair loss coupled with minimization of adverse effects result from the use of 5-alpha reductase inhibitors that are specific for the hair follicle or from the use of medications that work by alternate pathways. In addition, gene therapy may have future application in hair loss treatment. The genes that cause alopecia can be located and potentially replaced with genetic sequences not associated with hair loss.

Hair cloning (technically cell multiplication) may offer the surgeon a virtually unlimited supply of donor hairs. By cloning multiple copies of just a few donor hairs, patients with even extensive hair loss can expect complete scalp coverage, all with minimal donor-site morbidity. Most likely, follicle stem cells will be multiplied then injected into areas of thinning to initiate the regrowth of hairs. Candidates for hair cloning include those with advanced hair loss and those with scarring or poor supplies of potential donor hairs because of burn injury or previous poorly performed hair transplantations.

Mechanization of the hair-transplantation process is perhaps the only way to improve the process of follicular-unit transplantation. Instruments capable of rapidly and accurately dissecting the grafts and atraumatically placing the grafts will speed the process and reduce reliance upon assistants. However, hair transplantation will remain an aesthetic procedure that requires a skilled surgeon to create natural-appearing results.

According to the International Society of Hair Restoration Surgery, hair loss affects 21 million women in the United States, with varying impact on their psychological, social, and emotional well-being. Hair loss in men can be socially acceptable, and, in fact, deemed attractive or alluring. Conversely, society generally has less acceptance of thinning of hair or baldness in women. Women with hair loss often find it more difficult to share their feelings about hair loss with loved ones or friends or even their physicians.



The scalp is divided into five layers, which are easily remembered by the mnemonic SCALP, which represents, in order from outermost to innermost layer, the skin, connective subcutaneous tissue, galea aponeurosis, loose connective tissue, and periosteum over the cranium.

The skin contains all the epidermal appendages, including hair follicles, which extend into the connective subcutaneous layer. In areas that have undergone hair loss, thinning of the outer two layers usually occurs. This situation can be appreciated when one compares the thickness of the scalp in recipient areas with that in donor areas.

The subcutaneous layer is well vascularized and contains the main penetrating branches of the named main arteries that travel primarily along the external surface of the galea. The importance of staying superficial along the connective subcutaneous tissue layer (when one makes slit recipient sites to avoid compromising circulation) has only recently become apparent. The scalp has an excellent blood supply. The supraorbital, supratrochlear, superficial temporal, postauricular, and occipital arteries are the primary vessels, and they typically travel with the veins.

The galea aponeurotica is a nonelastic layer that connects the frontalis muscles anteriorly with the occipitalis muscle at its posterior aspect. The temporoparietal fascia, in which the superficial temporal artery travels, is also connected to the galea. The galea sliding over the loose connective-tissue layer allows for most scalp mobility. This loose connective-tissue layer and the periosteum below have minimal sensory innervation.

The sensory innervation of the scalp closely follows the vascular supply. At the anterior aspect, the supraorbital and supratrochlear nerves provide sensation to the anterior half of the scalp. On occasion, sensation to the frontal scalp can diminish for several weeks when a large number of graft recipient sites are made along the hairline. The occipital nerve serves the posterior half of the scalp, whereas the supraauricular and superficial temporal nerves contribute innervation from the sides.

Perhaps no anatomic feature of the scalp is more important with regard to hair transplantation than the microscopic distribution of hair. Scalp hairs usually do not grow individually; they most often grow in tiny follicular-unit bundles, which usually contain 2-3 hairs and occasionally 1 or 4 hairs. A follicular unit contains these 1-4 terminal hairs, a sebaceous gland element, and insertions of the arrector pili muscles, all wrapped in an adventitial tissue sheath. These follicular units are dispersed throughout the scalp, where non–hair-bearing skin constitutes up to 50% of the total tissue. By transplanting only these follicular units and dissecting away the 50% of unnecessary non–hair-bearing tissue, the most natural-appearing results can be attained.

See Scalp Anatomy and Hair Anatomy for more information.



In men, pattern baldness has been established as an androgen-mediated miniaturization process of genetically susceptible hair follicles. Women with pattern baldness are presumed to undergo the same process.

Pattern baldness requires linking of the hormone dihydrotestosterone (DHT) to susceptible hair follicles. In the body, DHT is created when the enzyme 5-alpha reductase converts testosterone. This conversion takes place in the bloodstream and locally in the scalp and other body tissues. DHT acts on genetically susceptible hair follicles to cause miniaturization of the hair, which eventually leads to follicle death.

Donor versus recipient dominance refers to the ability of hair grafts taken from an occipital donor area to grow and survive after transplantation to the frontal recipient site of alopecia. This phenomenon is explained by the presence of 5-alpha reductase in the cells of the recipient hair follicles. Again, this enzyme, found in skin, is responsible for conversion of testosterone to DHT. Even normal circulating amounts of testosterone may be excessively converted to DHT or the hair follicle may be abnormally receptive to DHT, creating androgenic alopecia. The donor follicles from occipital regions have less or no enzyme and thus are not influenced by hormonal factors. The mesenchyme-derived dermal papilla at the base of the mainly epithelial hair follicle controls the type of hair produced. This is probably the site through which androgens act on follicle cells by altering the regulatory paracrine factors produced by dermal papilla cells.

Recipient dominant conditions refer to a diseased recipient area, which destroys the healthy donor follicle when transplanted. These conditions include cicatricial or scarring alopecia, such as discoid lupus erythematosus, lichen planopilaris (lichen planus of skin and hair follicles), and other active scarring skin diseases of hair and scalp that attack the healing donor follicles. These diseases can be treated medically and when the condition resolves, healthy hair grafts can be placed into the resultant but quiescent scar.



Hair loss in men almost always is due to androgenic pattern baldness, which is usually referred to as male pattern baldness. Although the exact cause of pattern balding is unclear, the trait is transmitted by means of a polygenic type of inheritance. Anecdotal reports indicate a stronger link to men on the maternal side of the family than on the paternal side. Male pattern baldness is a progressive process that continues for the rest of an individual's lifetime. The eventual degree of hair loss is typically more advanced with a younger age of onset.

In women, most hair loss is also genetic, although women have an increased incidence of hair loss caused by medical conditions, such as hormonal imbalance, trichotillomania, and poststress telogen effluvium. Interestingly, even with androgenetic alopecia in women, there appears to be an additional inflammatory contribution to hair loss, as scalp biopsies often reveal a localization of lymphocytic folliculitis around the stem-cell–containing bulge region of the hair follicle.[5]  As with male pattern baldness, female pattern androgenic hair loss is progressive.

Alopecia areata is an autoimmune hair cycle shift that can be present in any area of the scalp, including donor areas, so that all scalp hairs may be involved, leaving no healthy donor follicles. It also resolves with medication and topical therapy, with hair regrowth in most instances. Diffuse female alopecia also involves the entire scalp and thus is not amenable to hair transplantation.

The most common cause of hair loss in women is androgenetic alopecia. Unlike androgenetic alopecia in men, women tend to have diffuse thinning, often sparing the frontal and occipital regions. Differentiating androgenetic alopecia in women from other causes of alopecia is important. A positive family history usually accompanies androgenetic alopecia. Increased sensitivity to androgen with normal serum hormone levels is present. The pattern usually preserves the frontal hairline. Miniaturized hairs with varying lengths and diameters are present.

Androgenetic alopecia must be differentiated from androgen excess disorders, which are often the result of adrenal, ovarian, or pituitary tumors or disorders.[6] Be suspicious of androgen excess if the following are present: hirsutism, menstrual disorders, cystic acne, galactorrhea, virilization with temporal recession, lowering of voice, increase in muscle mass (especially the shoulder girdle), and infertility. The workup is best performed by an endocrinologist or gynecological endocrinologist.

Rapidly thinning hair may suggest telogenic effluvium or endocrinopathies. Telogenic effluvium is best treated with minoxidil. Telogenic effluvium may be an acute generalized hair loss over the scalp, such as that occurring with stress, anesthesia, or childbirth. Hair regrowth usually occurs 4-12 months later. Chronic telogenic effluvium occurs more slowly and may be confused with androgenetic alopecia. Unlike the latter, chronic telogenic effluvium is not usually revealed in family history.

Hair loss in women can be caused by numerous sources, such as hypothyroidism, various medications, systemic disorders, trauma (eg, surgical trauma, burn alopecia), and infections. Telogenic effluvium and androgenetic alopecia can coexist, with an episode of telogenic effluvium unmasking coexistent androgenetic alopecia.

Scarring alopecia of unknown etiology is best evaluated by biopsy and dermatologic workup.

The other large group of women presenting for hair transplantation are those with postsurgical scarring. Usually these patients have undergone browlifts and facelifts.

Interest in eyebrow and eyelash transplantation has recently increased. The use of micrografting techniques with microscopes used for graft cutting has greatly improved these techniques. More recently, the use of follicular unit extraction (FUE), which is graft harvest with tiny micropunches, can decrease donor scarring.[7, 8] Eyebrow alopecia may result from plucking, trauma, or inherited thinning. Eyelash alopecia may also be traumatic, inherited, or caused by compulsive pulling or plucking.



The incidence of hair loss in men approaches 60% by the age of 60 years. In women, this incidence is considerably lower, that is, approximately 10% at a similar age.

Alopecia is a common problem within our population. In the United States, it is estimated that 35,000,000 men and 21,000,000 women experience hair loss. It is so common in men that it is actually accepted as normal.

Androgenic alopecia in females is an increasingly frequent problem based on heredity and hormonal change. There is much speculation concerning the more frequent occurrence of this problem among premenopausal women, but the answer remains obscure. Both of these conditions are considered "donor dominant" and thus amenable to hair transplant surgery.

Among racial groups, whites have the highest incidence of hair loss, African Americans have lowest incidence, and Asians have an incidence between the two.




Patients must be given realistic expectations. Furthermore, the importance of joint planning by the patient and the surgeon for future hair loss cannot be underestimated.

The transplanted hair follicles typically appear to grow in the immediate postoperative period. Within a month, the graft follicles enter the telogen phase and are all shed. Hair regrowth then takes approximately 4 months, but the hair continues to improve in quality and quantity over the subsequent 2-4 months. Growth stabilizes at about 1 year and reports have indicated graft survival rates of over 95% in experienced hands. Even 18 months after surgery, newly transplanted hairs have been observed to appear for the first time.

The present techniques and technology of hair transplantation surgery can give a proper candidate realistic and natural appearing transplanted hair. Using 2 or 3 hair transplant sessions, the candidate has a successful outcome.

Case 2. Views before and after 3500 follicular-uni Case 2. Views before and after 3500 follicular-unit micrografts performed in 2 procedures.
Case 2. Close-up view of the hairline of a patient Case 2. Close-up view of the hairline of a patient after transplantation of 3500 follicular-unit micrografts performed in 2 procedures.


When performed properly, the results of hair transplantation are virtually undetectable. However, complications can arise from errors of technique, poor planning, and unpredictable patient factors.

As with any surgery, hair transplantation poses possible risks. Excessive bleeding due to undiagnosed coagulation disorders or secondary to medications can be bothersome at the least and (in rare cases) life threatening at the worst. Infections and anesthesia problems are two other potential, although unlikely, complications.

Complications more unique to the hair transplantation procedure are rare but can occur. Scarring of the donor site can include hypertrophic scar formation due to excessive tension and perhaps even a tendency toward keloid formation. Alopecic scar formation can result from excessively tight suture placement or from hair follicle cauterization. Scarring of the recipient site was more common when large-graft transplantation was performed. Such scarring included ridging, cobblestoning, and skin hypopigmentation.

Poor hair growth can occur and probably is largely dependent on technique. Graft desiccation, rough handling of the grafts, and faulty graft preparation can result in limited hair growth. Lack of growth must be distinguished from delayed hair growth because transplanted hairs occasionally require as long as 12 months to grow. Telogen effluvium or loss of original hairs in transplanted areas, usually an avoidable condition, can result from poor circulation or inadvertent trauma to already existing hair follicles, thus producing an initial early thinning of hair that can range from mild to cosmetically disturbing. Hairs usually return in 1-2 months, but this can be a difficult situation.

Errors of technique and of poor planning are preventable but occur all too often. The most common of these technical errors, which results in a transplanted appearance, is the use of excessively large grafts and unaesthetic hairline design. The importance of using 1- and 2-hair grafts, placed in the proper direction to create an irregular hairline of gradually increasing density as the surgeon proceeds centrally, cannot be overstated.

Failure to anticipate future hair loss in planning hairline restoration can result in an unnatural appearance as the patient ages. One of the most common problems can be development of large bald areas between the lateral aspects of the parietal hairline and the temporal peaks caused by recession of the temporal areas. Transplanting of the crown in a young individual who eventually develops excessive baldness can result in a circular region of transplanted hair surrounded by a rim of bald scalp.

Undesirable hair transplantation results can usually be dramatically improved by using a number of reparative techniques. However, the goal of hair-transplant surgeons should be the prevention of undesirable results.

Complication rates in hair restoration surgery are very low. In one study, they occurred in 4.7% of patients and included enlarged scar (1.2%), folliculitis (1%), areas of necrosis in the donor area (0.8%), keloids (0.4%), bleeding (0.2%), hiccups (0.2%), infection (0.2%), and pyogenic granuloma (0.2%).[9] This survey included physicians whose practice was not limited to hair transplantation, where the percentages are higher than those reported elsewhere.[10]


Patient Education

As with any surgical procedure, thorough counseling before hair-restoration surgery is critical. Patients require education to make informed decisions regarding this elective procedure, ie, whether to undergo it, and, if so, which procedures. Because hair restoration is cosmetic surgery, discussing patients' areas of concern, explaining treatment options, and providing a realistic picture of expected results are important.

Patients should be provided with written information regarding both preoperative and postoperative instructions. After reviewing the patient’s list of medications to rule out any that may adversely interact with anesthesia administered during the procedure, it is important that various medications that may affect bleeding time be discontinued. Patients should stop taking all aspirin-containing medications, vitamin E, and ginkgo 10 days before the procedure and all nonsteroidal anti-inflammatory drugs (eg, ibuprofen) and alcohol 3 days before. To further reduce the risk of bruising and edema, patients are instructed to take vitamin C 2000 mg daily for 1 week before surgery. If the patient is to receive intravenous or twilight sedation, they should receive nothing by mouth (NPO) 8 hours before the procedure.

Appropriately aligning patient and physician expectations is critical during the initial evaluation and consultation. Understanding the limits of a patient’s donor hair reserves, their hair characteristics, and their goals and motivation for undergoing hair transplantation can best help evaluate and articulate a projected outcome. Establishing this mutual understanding is one of the most effective ways to increase overall patient satisfaction.

Contributor Information and Disclosures

Jeffrey S Epstein, MD, FACS Clinical Professor, Department of Otolaryngology, Division of Facial Plastic Surgery, University of Miami, Leonard M Miller School of Medicine; Consulting Surgeon, Foundations for Hair Restoration and Plastic Surgery

Jeffrey S Epstein, MD, FACS is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons

Disclosure: Nothing to disclose.


Carlos K Wesley, MD Private Practice in Hair Restoration Surgery

Carlos K Wesley, MD is a member of the following medical societies: American Academy of Cosmetic Surgery, International Society of Hair Restoration Surgery, American Hair Loss Association, International Alliance of Hair Restoration Surgeons

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Keith A LaFerriere, MD Clinical Professor, Fellowship Director, Department Otolaryngology-Head and Neck Surgery, University of Missouri-Columbia School of Medicine

Keith A LaFerriere, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, Missouri State Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan;RxRevu;SymbiaAllergySolutions<br/>Received income in an amount equal to or greater than $250 from: Symbia<br/>Received from Allergy Solutions, Inc for board membership; Received honoraria from RxRevu for chief medical editor; Received salary from Medvoy for founder and president; Received consulting fee from Corvectra for senior medical advisor; Received ownership interest from Cerescan for consulting; Received consulting fee from Essiahealth for advisor; Received consulting fee from Carespan for advisor; Received consulting fee from Covidien for consulting.

Additional Contributors

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John G Albertini, MD Private Practice, The Skin Surgery Center; Clinical Associate Professor (Volunteer), Department of Plastic and Reconstructive Surgery, Wake Forest University School of Medicine; President-Elect, American College of Mohs Surgery

John G Albertini, MD is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Surgery

Disclosure: Received grant/research funds from Genentech for investigator.

Joseph A Molnar, MD, PhD, FACS Medical Director, Wound Care Center, Associate Director of Burn Unit, Professor, Department of Plastic and Reconstructive Surgery and Regenerative Medicine, Wake Forest University School of Medicine

Joseph A Molnar, MD, PhD, FACS is a member of the following medical societies: American Medical Association, American Society for Parenteral and Enteral Nutrition, American Society of Plastic Surgeons, North Carolina Medical Society, Undersea and Hyperbaric Medical Society, Peripheral Nerve Society, Wound Healing Society, American Burn Association, American College of Surgeons

Disclosure: Received grant/research funds from Clinical Cell Culture for co-investigator; Received honoraria from Integra Life Sciences for speaking and teaching; Received honoraria from Healogics for board membership; Received honoraria from Anika Therapeutics for consulting; Received honoraria from Food Matters for consulting.

Jorge I de la Torre, MD, FACS Professor of Surgery and Physical Medicine and Rehabilitation, Chief, Division of Plastic Surgery, Residency Program Director, University of Alabama at Birmingham School of Medicine; Director, Center for Advanced Surgical Aesthetics

Jorge I de la Torre, MD, FACS is a member of the following medical societies: American Burn Association, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Society of Maxillofacial Surgeons, American Society of Plastic Surgeons, American Society for Reconstructive Microsurgery, Association for Academic Surgery, Medical Association of the State of Alabama

Disclosure: Nothing to disclose.

Robert S Bader, MD Dermatologist, Section of Dermatology, Department of Medicine, Broward Health - North

Robert S Bader, MD is a member of the following medical societies: American Academy of Dermatology, Florida Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery

Disclosure: Nothing to disclose.

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

J David Kriet, MD, FACS Associate Professor, Department of Otolaryngology-Head and Neck Surgery, Director of Facial Plastic and Reconstructive Surgery, University of Kansas School of Medicine

J David Kriet, MD, FACS is a member of the following medical societies: Society of University Otolaryngologists-Head and Neck Surgeons, AO Foundation, Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Cleft Palate-Craniofacial Association, American College of Surgeons, American Medical Association

Disclosure: Received honoraria from AO North America for speaking and teaching.

Mark E Krugman, MD Assistant Professor of Plastic Surgery, Clinical Professor of Otolaryngology-Head and Neck Surgery, University of California at Irvine School of Medicine

Mark E Krugman, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Society of Plastic Surgeons, American Academy of Facial Plastic and Reconstructive Surgery, American Society for Aesthetic Plastic Surgery, American Society for Laser Medicine and Surgery

Disclosure: Nothing to disclose.

R Stan Taylor, MD The JB Howell Professor in Melanoma Education and Detection, Departments of Dermatology and Plastic Surgery, Director, Skin Surgery and Oncology Clinic, University of Texas Southwestern Medical Center

R Stan Taylor, MD is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Surgery, American Medical Association

Disclosure: Nothing to disclose.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Walter P Unger, MD FRCP(C), FACP, ABHRS, Clinical Professor, Department of Dermatology, Director, Cosmetic Dermatologic Fellowship Program, Mount Sinai School of Medicine; Associate Professor, Department of Medicine (Dermatology), University of Toronto Faculty of Medicine

Walter P Unger, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Canadian Medical Association, Ontario Medical Association, Canadian Dermatology Association, International Society of Hair Restoration Surgery

Disclosure: Nothing to disclose.

  1. Wesley CK, Unger RH, Unger WP. Hair Transplantation. Thorne et al, eds. Grabb and Smith’s Plastic Surgery. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2013. 549-64.

  2. Bunagan MJ, Banka N, Shapiro J. Hair transplantation update: procedural techniques, innovations, and applications. Dermatol Clin. 2013 Jan. 31 (1):141-53. [Medline].

  3. Williams KL Jr. Current practices and controversies in cosmetic hair restoration. Dermatol Surg. 2013 May. 39 (5):797-801. [Medline].

  4. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975 Nov. 68 (11):1359-65. [Medline].

  5. Magro CM, Rossi A, Poe J, Manhas-Bhutani S, Sadick N. The role of inflammation and immunity in the pathogenesis of androgenetic alopecia. J Drugs Dermatol. 2011 Dec. 10 (12):1404-11. [Medline].

  6. Redmond GP. Androgenic disorders of women: diagnostic and therapeutic decision making. Am J Med. 1995 Jan 16. 98 (1A):120S-129S. [Medline].

  7. Rassman WR, Bernstein RM, McClellan R, Jones R, Worton E, Uyttendaele H. Follicular unit extraction: minimally invasive surgery for hair transplantation. Dermatol Surg. 2002 Aug. 28 (8):720-8. [Medline].

  8. Harris JA. Powered blunt dissection with the SAFE System for FUE. Hair Transplant Forum International. Nov/Dec 2011. 20:188-89.

  9. Salanitri S, Gonçalves AJ, Helene A Jr, Lopes FH. Surgical complications in hair transplantation: a series of 533 procedures. Aesthet Surg J. 2009 Jan-Feb. 29 (1):72-6. [Medline].

  10. Knudsen RG, Unger M. Unger W, et al. Hair Transplantation. 5th ed. New York, NY: Marcel Dekker; 2011. 419-22.

  11. Chiang YZ, Tosti A, Chaudhry IH, Lyne L, Farjo B, Farjo N, et al. Lichen planopilaris following hair transplantation and face-lift surgery. Br J Dermatol. 2012 Mar. 166 (3):666-370. [Medline].

  12. Wesley CK. Enhanced Patient Selection: The Folliscope. Unger and Shapiro, eds. Hair Transplantation. 5th ed. New York, NY: Marcel Dekker; 2011. 82-3.

  13. Jimenez JJ, Wikramanayake TC, Bergfeld W, Hordinsky M, Hickman JG, Hamblin MR, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol. 2014 Apr. 15 (2):115-27. [Medline].

  14. Epstein JS. Hair transplantation in women: treating female pattern baldness and repairing distortion and scarring from prior cosmetic surgery. Arch Facial Plast Surg. 2003 Jan-Feb. 5 (1):121-6. [Medline].

  15. Frechet P. Donor harvesting with invisible scars. Hair Transplant Forum Intl. 2005. 15(4):119-20.

  16. Nordström RE, Greco M, Vitagliano T. Correction of sideburn defects after facelift operations. Aesthetic Plast Surg. 2000 Nov-Dec. 24 (6):429-32. [Medline].

  17. Barrera A. The use of micrografts and minigrafts in the aesthetic reconstruction of the face and scalp. Plast Reconstr Surg. 2003 Sep. 112 (3):883-90. [Medline].

  18. Harris JA. Follicular unit transplantation: dissecting and planting techniques. Facial Plast Surg Clin North Am. 2004 May. 12 (2):225-32. [Medline].

  19. Lee SJ, Lee HJ, Hwang SJ, Kim DW, Jun JB, Chung SL, et al. Evaluation of survival rate after follicular unit transplantation using the KNU implanter. Dermatol Surg. 2001 Aug. 27 (8):716-20. [Medline].

  20. Haber RS, Unger M, Unger W, et al. Hair Transplantation. 5th ed. New York, NY: Marcel Dekker; 2011. 279-80.

  21. Rashid RM, Morgan Bicknell LT. Follicular unit extraction hair transplant automation: options in overcoming challenges of the latest technology in hair restoration with the goal of avoiding the line scar. Dermatol Online J. 2012 Sep 15. 18 (9):12. [Medline].

  22. Seager DJ. Micrograft size and subsequent survival. Dermatol Surg. 1997 Sep. 23 (9):757-61; discussion 762. [Medline].

  23. Limmer R. Micrograft survival. Stough D, Haber R, eds. Hair Replacement. St. Louis, Mo: Mosby; 1996. 147-49.

  24. Kim JC. Unger W, Shapiro R, et al. Hair Transplantation. 5th ed. New York, NY: Marcel Dekker; 2011. 404-6.

  25. Unger WP. Delineating the "safe" donor area for hair transplanting. Am J Cosmetic Surg. 1994. 239-43.

  26. Wesley CK, Teo LH, Xu T, Unger RH, Unger WP. The influence of peri-incisional triamcinolone acetonide injection on wound edge apposition. J Dermatolog Treat. 2014 Aug. 25 (4):345-9. [Medline].

Case 1. Views before and 6 months after a procedure performed by using 2000 follicular-unit micrografts.
Case 1. Close-up view of the hairline of a patient 6 months after a procedure performed by using 2000 follicular-unit micrografts.
Case 2. Views before and after 3500 follicular-unit micrografts performed in 2 procedures.
Case 2. Close-up view of the hairline of a patient after transplantation of 3500 follicular-unit micrografts performed in 2 procedures.
Medscape Consult
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.